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Bryant et al General Thoracic SurgeryClimbing several flights of stairs:
___ Yes, limited a lot
___ Yes, limited a little
___ No, not limited at allDuring the PAST 4 WEEKS have you had any of the fol-
lowing problems with your work or other regular activities
AS A RESULT OF YOUR PHYSICAL HEALTH?
3. Accomplished less than you would like:___ Yes
___ No4. Were limited in the KIND of work or other activities:___ Yes
___ NoSDuring the PAST 4WEEKS, were you limited in the kind
of work you do or other regular activities ASARESULTOF
ANY EMOTIONAL PROBLEMS (such as feeling de-
pressed or anxious)?
5. ACCOMPLISHED LESS than you would like:G
T___ Yes
___ No6. Didn’t do work or other activities as CAREFULLY as
usual:___ Yes
___ No7. During the PAST 4 WEEKS, how much did PAIN inter-
fere with your normal work (including both work outside
the home and housework)?___ Not at all
___ A little bit
___ Moderately
___ Quite a bit
___ ExtremelyThe next three questions are about how you feel and how
things have been DURING THE PAST 4WEEKS. For each
question, please give the one answer that comes closest to
the way you have been feeling. How much of the time
during the PAST 4 WEEKS
8. Have you felt calm and peaceful?___ All of the time
___ Most of the time
___ A good bit of the time
___ Some of the timeThe Journal of Thoracic and Cardiov___ A little bit of the time
___ None of the time9. Did you have a lot of energy?___ All of the time
___ Most of the time
___ A good bit of the time
___ Some of the time
___ A little bit of the time
___ None of the time10. Have you felt downhearted and blue?___ All of the time
___ Most of the time
___ A good bit of the time
___ Some of the time
___ A little bit of the time
___ None of the time11. During the PAST 4WEEKS, how much of the time has
your PHYSICAL HEALTH OR EMOTIONAL PROB-
LEMS interfered with your social activities (like visit-
ing with friends, relatives, etc.)?___ All of the time
___ Most of the time
___ A good bit of the time
___ Some of the time
___ A little bit of the time
___ None of the timeDiscussion
Dr Gary W. Chmielewski (Chicago, Ill). I would like to con-
gratulate Dr Bryant on a good presentation and I would like to
thank the authors for getting the manuscript to Dr Liptay and I
before the meeting. Dr Liptay and I would like to thank the Asso-
ciation for the chance to review this and discuss.
As surgeons, we have 2 goals in performing a pulmonary resec-
tion. One is to get rid of the cancer and the other is to get patients
back to their lives. The authors are to be congratulated on looking
at the second part of the equation, which most often is overlooked.
In this paper, the authors look at postoperative QOL scores in
patients undergoing pneumonectomy. They report on 111 patients
operated on during a 13-year period. Five-year survivals were
37%, with QOL scores obtained in 98% of these patients who
were out 1 year from surgery. In summary, the mental quality of
life scores were better compared with to the average population
whereas the physical component score was significantly worse
than the average population. As was pointed out here, in their ar-
ticle the authors state that it’s a misnomer to call a pneumonectomy
a disease, and they also emphasized the need to use separateascular Surgery c Volume 144, Number 5 1143
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Smental and physical parameters to assess the impact of our surgery
on our patients’ quality of life. Although I agree with the authors
that the QOL scores are important in looking at our overall surgical
results, it does appear from your data that we are inducing some-
what of a chronic disease state on these patients, because they do
have QOL scores physically that are worse than patients with heart
disease, renal disease, and diabetes mellitus.
That said, I have 3 questions. The first 2 are: Now that your in-
stitution is armed with these data, do your surgeons plan to give
a preoperative QOL questionnaire and, if there are surgeons in
the audience who are inclined to go ahead and use these question-
naires in their postoperative care, what interval do you suggest that
we query our patients on?
Dr Bryant. Based on these data, we do plan to implement not
only just the QOL survey but physiologic measurements as well,
such as PFTs and a 6-minute walk test. I think a 6-month interval
for the first few years postoperatively would be ideal, and then
yearly for the remainder of the patient’s life, or as far as
possible.
Dr Chmielewski. This is an uncommon circumstance, but did
you see any dramatic differences in the QOL scores in the rare
patient who required a right pneumonectomy who also received
neo-adjuvant therapy compared with the rest of the group?
Dr Bryant. In our patient cohort we did not see any differences.
Dr Chmielewski.My final question is: Have your data resulted
in the surgeons at your institution selecting patients differently for
pneumonectomy or, I guess I’d like to ask Cerf, do you plan to
manage any of these preoperative or postoperative parameters dif-
ferently so that we can improve on our patients’ QOL?
Dr Cerfolio. This is the one that Cam should be getting up and
giving me the business on, not the other one. This paper was really
Dr Bryant’s idea, not mine—QOL. I said, you know, QOL, really,
I’m a surgeon. But these are great data. And when she collected the
data, I was really depressed to see several things: That 40 patients
out of 150 are dead at a year. That’s embarrassing, but that’s my
own data. They were all R0 resections and they all were N2 nega-
tive on mediastinoscopy, endobronchial ultrasound, or frozen at
the time of surgery. I think 6 or 7 ended up having N2 positive
on final pathology. But I thought I picked the best of the best,
and 1 in 3 are dead at a year. That’s not very good.
Dr Shrager.Most of them were stage IB, right? That would be
better than the published data for stage IB.
Dr Cerfolio. Well, I appreciate you saying that, but I’m not
happy with the results. And then to find out that the two thirds
who are alive aren’t really very happy with their QOL, especially
if they’re old. So I have gotten less aggressive. So now it looks like
the only way to get an R0 resection is to do a pneumonectomy. I am
having a different conversation since Dr Bryant has presented me
with this data, to be honest. My initial thing when I wrote the
abstract was, oh, pneumonectomy is a disease really is a misnomer;
it’s not a disease, but it depends how you define disease, and if you
define hypertension and diabetes mellitus and chronic liver disease
as a disease, and I guess we should, then a pneumonectomy is
a disease, and so I’m wrong. What else new?
Dr Todd L. Demmy (Buffalo, NY). The SF-12 is an abbreviated
form of the SF-36. The 2 dimensions on these studies that people
get a major effect after lung resection tend to be dyspnea and pain.
Is the ability to measure those dimensions reduced on the SF-12?1144 The Journal of Thoracic and Cardiovascular SurDr Bryant. On the SF-12, the questions that are asked are more
about are you able to perform your activities of daily life. Indi-
rectly, it’s asking about their functional status. We actually added
a few questions in our survey that address specifically those issues,
pain, but we did not find any correlations.
Dr Demmy. It’s interesting to study that interaction because
with more lung resected there is more muscle use, probably aggra-
vating the chronic pain mechanism. So I think you should look at
that. The other data point that tends to categorize the QOL on these
surveys is diffusing capacity rather than FEV1. Did you break out
your scores based on the DLCO?
Dr Bryant. We did. We looked at both FEV1 and DLCO. We
did not find a correlation with DLCO. It may be that the patients
with the poorest PFT status may have expired within that first year.
DrDemmy.Usually as you approach 40%DLCO, that’s a group
that does much worse with QOL. So you should analyze based on
those levels of residual diffusing capacity.
Dr Rafael S. Andrade (Minneapolis, Minn). I’m very im-
pressed with compliance of 98% in answering the surveys, which
I think would be good for a clinical trial. How did you actually do
that? In Minnesota, the IRB is very insistent that you can contact
patients maybe up to 3 times by letter, but you can’t be hammering
them. And some of these patients are 12 years out. They have no
reason to come back. How did you get 98% compliance?
Dr Bryant.We primarily mailed the surveys and then followed
up with a phone call. Our IRB did not make a stipulation of how
many times we could contact them. Every patient that Dr Cerfolio
has operated on since 1996, we have obtained permission to in-
clude their data in his prospective database, and we tell them up
front that this may be used for research. I think that’s one of the
reasons that the IRB gave us permission and allowed us to waive
consent. But it was very aggressive mail-outs and phone calls to
get that 98% response.
Dr Betty C. Tong (Durham, NC). I have 2 questions. First, how
do you think your data might be different or more robust if you had
longitudinal data?
Dr Bryant. I think it would help with assessing temporal
changes.
Dr Tong. Second, would you discuss a little bit how you chose
the SF-12 as your measure of QOL rather than another validated
measure, such as the European Organization for Research and
Treatment of Cancer (EORTC) Quality of Life Component 30
with the LC13 module, which is geared specifically toward pa-
tients with lung cancer.
Dr Bryant.We chose the SF-12 primarily because it’s a shorter
version of the survey and we were trading off compliance and pa-
tient response. With the longer surveys we found that patients
often didn’t respond or the survey was incomplete. With the SF-
12, we found that they are more likely to respond and complete
the survey.
Dr Tong. I think that the EORTCQuality of Life Component 30
with the LC13module, although longer, would address some of the
things that Dr Demmy had highlighted with regard to pain, short-
ness of breath, and other symptoms.
Dr Cerfolio. I would like to add one response to that. We tried
that before and failed. Patients in Alabama, and maybe it’s
Alabama, but people who come to see me, they’re not going to
spend time filling out more forms than they already have to justgery c November 2012
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Sfor the hospital and insurance company, and now answering more
questions for research stuff. Sowe did that before and we had a low
compliance. This is much higher with the 12 instead of the 36.
Dr David J. Sugarbaker (Boston, Mass). I just wanted to
congratulate Dr Cerfolio and the group on a really carefully
done study. I think it really highlights that when you say the
word pneumonectomy, it means different things to different peo-
ple, and if you select your patients well and the operation goes
well, those patients can live a very happy, relatively normal life.
So when you hear people talk about pneumonectomy, or even ex-
trapleural pneumonectomy, it means different things to different
people, but I think what these data show is that it can mean good
things for our patients. Congratulations.
Dr Gail Darling (Toronto, Ontario, Canada). I would just like
to follow along on the previous question about the instrument that
was chosen. I congratulate you for addressing QOL in our patients,
but I think, as surgeons, we should remember that QOL is not just
physical symptoms and debility and that sort of thing. There are
many other components to QOL. It’s not just their FEV1 or their
pain scores. I think some of the other instruments, the EORTC in-
strument, the FACT, measure some of these other dimensions of
QOL, including things like emotional well-being, social well-
being, functional well-being, which are not really captured by
the SF-12 or SF-36.
Dr Bryant. Thank you.
Dr Gaetano Rocco (Naples, Italy). I would like to ask a ques-
tion, Cerf. Could confounding factors in the analysis of the results
be the age threshold that you chose of 58 and the fact that more
than 10% of these patients were completion pneumonectomies?
DrCerfolio. I appreciate you trying to make me feel better. Yes.
Some of these were completion pneumonectomies and some of
these were destroyed lungs and difficult operations—not justThe Journal of Thoracic and Carcancer patients—but I have to also look in the mirror and be honest
and reflective about the poor reflection that is not very appealing,
and say that a 9-out-of-150 operative mortality and then an 11-out-
of-150 90-day mortality is not so good, and another 29 died within
a year. That’s pretty ugly. I think they were a sick group of patients,
I agree, but I think everybody in this room operates on a group of
sick patients. Howwould they have done if they had never meet me
is the other question we need more data on.
Dr Mohamed Khereba (Montreal, Quebec, Canada). You
compared your QOLwith hypertension and patients with renal dis-
ease. What kind of renal disease exactly? Is it terminal renal dis-
ease or just a patient with a different creatinine? What kind of
liver disease? A patient with severely debilitating liver disease
or not? If we are comparing pneumonectomy with a patient with
just working hypertension who has better control with 1 or 2 med-
ications, it’s not a disease as we would call it.
Dr Bryant. That’s an excellent question and a comment. I think
that’s one of the limitations of our study. The definitions of those
diseases were not clear. The reason that we used these data to
show as comparison data is that it’s really actually one of the
few data points that we found that is comparable, and it’s also re-
leased by the same company that makes the SF-12. So we felt that
it was comparable, but perhaps not the ideal.
Dr Khereba. I would suggest maybe you can compare them
with terminal renal disease, with very severe chronic obstructive
pulmonary disease, with patients after pneumonectomy with
some debilitating disease with a patient who has a very morbid
procedure like pneumonectomy.
Dr Joseph B. Shrager (Stanford, Calif). In most studies that
have looked at this, the control group is lobectomy patients. I
don’t know if you have the data, but you probably really want to
compare pneumonectomy patients with lobectomy patients.diovascular Surgery c Volume 144, Number 5 1145
